Model-based economic evaluation in Alzheimer's disease: A review of the methods available to model Alzheimer's disease progression

Value in Health

Volumn 14, Issue 5, 2011, Pages 621-630

  Green, Colin ^a   Shearer, James ^a   Ritchie, Craig W ^b   Zajicek, John P ^a,c  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

Alzheimer's disease; cost effectiveness analysis; health technology assessment; modelling methods

Indexed keywords

ALZHEIMER DISEASE; CLINICAL EVALUATION; COGNITION; DISEASE COURSE; DISEASE MODEL; ECONOMIC EVALUATION; HUMAN; MEDICAL LITERATURE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL MODEL; SYSTEMATIC REVIEW;

EID: 80052438829     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.12.008     Document Type: Article

References (69)

1. M. Knapp, M. Prince, and E. Albanese Dementia UK 2007 2007 Alzheimer's Society London
2. M. Gold, J. Siegel, L. Russell, and M. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
3. M. Weinstein, E. Toy, and E. Sandberg Modeling for health care and other policy decisions: uses, roles, and validity Value Health 4 2001 348 361 (Pubitemid 32946233)
4. R. Davies, P. Roderick, and J. Raftery The evaluation of disease prevention and treatment using simulation models Eur J Oper Res 150 2003 53 66
5. B. Unal, S. Capewell, and J. Critchley Coronary heart disease policy models: a systematic review BMC Public Health 6 2006 213
6. K. Cooper, S. Brailsford, R. Davies, and J. Raftery A review of health care models for coronary heart disease interventions Health Care Manag Sci 9 2006 311 324 (Pubitemid 44736856)
7. C. Green Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis PharmacoEcon 25 2007 735 750 (Pubitemid 47481639)
8. J. Caro Pharmacoeconomic analyses using discrete event simulation Pharmacoeconomics 23 2005 323 332 (Pubitemid 40677051)
9. J. Cohen, and P. Neumann Decision analytic models for Alzheimer's disease: state of the art and future directions Alzheimers Dement 4 2008 212 222 (Pubitemid 351682261)
10. M. Oremus Systematic review of economic evaluations of Alzheimer's disease medications Expert Rev Pharmacoeconomics Outcomes Res 8 2008 273 289 (Pubitemid 351959535)
11. A. Brennan, S. Chick, and R. Davies A taxonomy of model structures for economic evaluation of health technologies Health Econ 15 2006 1295 1310 (Pubitemid 44941606)
12. M. Sculpher, E. Fenwick, and K. Claxton Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application PharmacoEcon 17 2000 461 477 (Pubitemid 30398805)
13. M. Weinstein, B.J. O'Brien, and J. Hornberger Principles of good practice for decision-analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practicesmodeling studies Value Health 6 2003 9 17 (Pubitemid 36228345)
14. Z. Philips, L. Bojke, M. Sculpher, K. Claxton, and S. Golder Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment PharmacoEcon 24 2006 355 371
15. E. Loveman, C. Green, and J. Kirby The clinical and cost-effectiveness of donepezil, rivastigamine, galantamine and memantine for Alzheimer's disease Health Technol Assess 10 2006
16. J. McDonnell, W.K. Redekop, and N. van der Roer The cost of treatment of Alzheimers disease in the Netherlands: a regression-based simulation model Pharmacoeconomics 19 2001 379 390 (Pubitemid 32319931)
17. B. Kinosian, E. Stallard, and J. Lee Predicting 10-year care requirements for older people with suspected Alzheimer's disease J Am Geriatr Soc 48 2000 631 638 (Pubitemid 30390452)
18. P.J. Neumann, S.S. Araki, and A. Arcelus Measuring Alzheimer's disease progression with transition probabilities:Estimates from CERAD Neurology 57 2001 957 964 (Pubitemid 32880186)
19. J.C. Morris The Clinical Dementia Rating (CDR): current version and scoring rules Neurology 43 1993 2412 2414 (Pubitemid 23346995)
20. P.J. Neumann, R.C. Hermann, and K.M. Kuntz Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Neurology 52 1999 1138
21. S. Kirbach, K. Simpson, P. Nietert, and J. Mintzer A Markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's Disease Clin Drug Invest 28 2008 291 303 (Pubitemid 351521382)
22. J.-L. Fuh, and S.-J. Wang Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan Int J Geriatr Psychiatry 23 2007 73 78
23. J. López-Bastida, W. Hart, L. Garcia-Perez, and R. Linertova Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease J Alzheimers Dis 16 2009 399 407
24. S. Ikeda, Y. Yamada, and N. Ikegami Economic evaluation of donepezil treatment for Alzheimer's disease in Japan Dement Geriatr Cogn Disord 13 2002 33 39 (Pubitemid 33153186)
25. J. Martikainen, H. Valtonen, and T. Pirttil Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients Eur J Health Econ 5 2004 136 142 (Pubitemid 38832956)
26. S. Kulasingam, G. Samsa, and D. Zarin When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis Value Health 6 2003 542 550 (Pubitemid 37187716)
27. P. McMahon, S. Araki, and P. Neumann Cost-effectiveness of functional imaging tests in the doagnosis of Alzheimer disease Radiology 217 2000 58 68 (Pubitemid 33097579)
28. P. McMahon, S. Araki, P. Neumann, G. Harris, and G. Gazelle Cost-effectiveness of PET in the diagnosis of Alzheimer disease Radiology 228 2003 515 522 (Pubitemid 36910096)
29. M. Mendiondo, J. Ashford, R. Kryscio, and F. Schmitt Modelling Mini Mental State examination changes in Alzheimer's disease Stat Med 19 2000 1607 1616 (Pubitemid 30346250)
30. G. Small, D. Kaufer, M. Mendiondo, P. Quarg, and R. Spiegel Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years Int J Clin Pract 59 2005 473 477 (Pubitemid 40467894)
31. J. Caro, D. Getsios, and K. Migliaccio-Walle Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care Neurology 57 2001 964 971 (Pubitemid 32880187)
32. Y. Stern, M.-X. Tang, and M.S. Albert predicting time to nursing home care and death in individuals with Alzheimer disease JAMA 277 1997 806 812 (Pubitemid 27111316)
33. D. Getsios, J. Caro, G. Caro, and K. Ishak Assessment of health economics in Alzheimer's disease (AHEAD) Neurology 57 2001 972 978
34. D. Getsios, K. Migliaccio-Walle, and J. Caro NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? PharmacoEcon 25 2007 997 1006 (Pubitemid 350208905)
35. C. Green, J. Picot, and E. Lovemen Modelling the cost effectiveness of cholinesterase inhibitors in the management of of mild to moderately severe Alzheimer's Disease PharmacoEcon 23 2005 1271 1282 (Pubitemid 41803322)
36. J. Caro, M. Salas, and A. Ward Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries Drugs Aging 21 2004 677 686 (Pubitemid 39128000)
37. A. Ward, J. Caro, and D. Getsios Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK Int J Geriatr Psychiatry 18 2003 740 747 (Pubitemid 37009757)
38. K. Migliaccio-Walle, D. Getsios, and J.J. Caro Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States Clin Ther 25 2003 1806 1825 (Pubitemid 36801950)
39. F. Garfield, D. Getsios, J. Caro, A. Wimo, and B. Winblad Asessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden PharmacoEcon 20 2002 629 637
40. J. Caro, M. Salas, A. Ward, D. Getsios, and A. Mehnert Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands Dement Geriatr Cogn Disord 14 2002 84 89 (Pubitemid 36152949)
41. R. Jones, P. McCrone, and C. Guillhaume Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective Drugs Aging 21 2004 607 620 (Pubitemid 39070995)
42. B. Reisberg, R. Doody, and A. Stoffler Memantine in Moderate-to-Severe Alzheimer's Disease N Engl J Med 348 2003 1333 1341 (Pubitemid 36384100)
43. G. Livingston, C. Katona, and B. Roch A dependency model for patient's with Alzheimer's disease: its validation and relationship to the costs of care: the LASER-AD study Curr Med Res Opin 57 2004 1007 1016 (Pubitemid 38954463)
44. M. Gagnon, B. Rive, M. Hux, and C. Guilhaume Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada Can J Psychiat 52 2007 519 526 (Pubitemid 47403186)
45. F. Antonanzas, B. Rive, J. Badenas, S. Gomez-Lus, and C. Guilhaume Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaption in Spain Eur J Health Econ 2 2006 137 144 (Pubitemid 44562258)
46. L. Jönsson Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden Am J Geriatr Pharmacother 3 2005 77 86 (Pubitemid 41200509)
47. C. Francois, H. Sintonen, R. Sulkava, and B. Rive Cost-effectiveness of memantine in moderately severe to severe Alzheimer's disease Clin Drug Invest 24 2004 373 384 (Pubitemid 38951789)
48. J. Kirby, C. Green, and E. Loveman A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease Drugs Aging 23 2006 227 240
49. P. Fenn, and A. Gray Estimating long-term cost savings from treatment of Alzheimer's disease: a modelling approach Pharmacoeconomics 16 1999 165 174 (Pubitemid 29450604)
50. M. Rösler, R. Anand, and A. Cicin-Sain Safety and efficacy of rivastigmine in patients with Alzheimer's disease BMJ 318 1999 633 638
51. J. Corey-Bloom, R. Anand, and J. Veach A randomized trial evaluating th efficacy and safety of rivastigmine J Clin Psychopharm 1 1998 55 65
52. A. Hauber, A. Gnanasakthy, and J. Mauskopf Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine Clin Ther 22 2000 439 451 (Pubitemid 30304795)
53. A. Hauber, A. Gnanasakthy, and E.H. Snyder Potential savings in the cost of caring for Alzheimer's disease: treatment with rivastigmine Pharmacoecon 17 2000 351 360 (Pubitemid 30236170)
54. L. Jönsson, P. Lindgren, and A. Wimo Costs of Mini Mental State Examination-related cognitive impairment Pharmacoeconomics 16 1999 409 416 (Pubitemid 29496050)
55. L. Jönsson, P. Lindgren, and A. Wimo The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: A Markov model Clin Ther 21 1999 1230 1240 (Pubitemid 29380477)
56. S. Teipel, M. Ewers, and V. Reisig Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease Eur Arch Psychiatry Clin Neurosci 257 2007 330 336 (Pubitemid 47485284)
57. D. Weycker, C. Taneja, and J. Edelsberg Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Curr Med Res Opin 23 2007 1187 1197 (Pubitemid 46799603)
58. F. Schmitt, W. Ashford, and C. Ernesto The Severe Impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease Alz Dis Assoc Dis 11 Suppl. 1997 S51 S56
59. R.G. Stern, R.C. Mohs, and M. Davidson A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration Am J Psychiatry 151 1994 390 396 (Pubitemid 24081459)
60. C. Green, R. Mohs, and J. Schmeidler Functional decline in Alzheimer's disease: a longitudinal study J Am Geriatr Soc 41 1993 654 661 (Pubitemid 23171685)
61. C. Wattmo, O. Hansson, and.K. Wallin Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting Dement Geriatr Cogn Disord 26 2008 203 211
62. F. Fagnani, A. Lafuma, and M. Pechevis Donepezil for the treatment of mild to moderate Alzheimer's Disease in France: the economic implications Dement Geriatr Cogn Disord 17 2004 5 13 (Pubitemid 37499961)
63. H. Nathan, L.L. Krista, and S. Robert The contribution of neuropsychiatric symptoms to the cost of dementia care Int J Geriatr Psychiatry 21 2006 972 976
64. C.W. Zhu, N. Scarmeas, and R. Torgan Clinical features associated with costs in early AD: baseline data from the Predictors Study Neurology 66 2006 1021 1028 (Pubitemid 44044785)
65. C.W. Zhu, N. Scarmeas, and R. Torgan Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease Neurology 67 2006 998 1005 (Pubitemid 44454592)
66. J. Hill, H. Fillit, S. Thomas, and S. Chang Functional impairment, healthcare costs, and the prevalence of institutionalisation in patients with Alzheimer's Disease and other dementias Pharmacoeconomics 24 2006 265 280 (Pubitemid 43374378)
67. R.E. Tractenberg, P.S. Aisen, M.F. Weiner, J.L. Cummings, and G.R. Hancock Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach Alzheimers Dement 2 2006 303 313 (Pubitemid 44524777)
68. R. Tractenberg, M. Weiner, and J. Cummings Independence of changes in behaviour from cognition and function in community-dwelling persons with Alzheimer's Disease: a factor analytical approach J Neuropsychiatry Clin Neurosci 17 2005 51 60 (Pubitemid 40283770)
69. A. Wimo, G. Karlsson, A. Nordberg, and B. Winblad Treatment of Alzheimer disease with tacrine: a cost-analysis model Alz Dis Assoc Dis 11 1997 191 200 (Pubitemid 28029558)